Allosteric modulators for human health
Addex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Plan-les-Ouates, Geneva, Switzerland, focused on the discovery and development of novel orally available small molecule allosteric modulators for neurological disorders. The company's pipeline includes programs targeting mGlu5, mGlu2, mGlu7, and GABAB receptors for indications including post-stroke recovery, traumatic brain injury, substance use disorder, chronic cough, and anxiety-related disorders. Addex also launched a spin-out, Neurosterix, to advance M4 PAM allosteric modulators for schizophrenia. The company trades on SIX Swiss Exchange and has US ADRs listed.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountAug 2022
Mar 2018
Feb 2017
Aug 2013
May 2007
Sep 2006
Oct 2005
Dec 2004
Create a free account to see which investors have funded this company.
Create Free Account
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
